



Newborn Screening Quality Assurance Program

PROFICIENCY TESTING PROGRAM FOR ANTI-HIV-1 IN DRIED BLOOD SPOTS

Quarterly Report

Quarter 3

August 2011

INTRODUCTION

The Anti-HIV-1 proficiency testing (PT) panel for Quarter 3, 2011, consisted of five individual-matrix dried-blood spot (DBS) specimens representing a variety of serostatuses. HIV antibody screening and confirmatory tests should identify all HIV-positive specimens, regardless of subtype. Method and laboratory performance are evaluated by challenging participants with specimens representing HIV-negative and positive serostatuses.

On July 18, 2011, we sent the Quarter 3 Anti-HIV-1 panel to 28 total participants. We received data reports from 25 participating laboratories by the designated deadline date. This report is the outcome of data reported for the Quarter 3, 2011, Anti-HIV-1 PT specimens. This quarterly report is distributed to all participants and to program colleagues upon request.

Each participant was asked to analyze the specimens for anti-HIV-1 using the assay schemes they routinely use and to report for each

specimen the screening results along with results from any confirmatory assays performed for presumptive positives. A final interpretation for each specimen must be submitted to receive a grade.

PARTICIPANTS' RESULTS

Table 1 shows the overall frequency of reported reactive, non-reactive, and indeterminate screening results for specimens 3141-3145.

In Part 1 of the report, Table 2 shows the number of laboratories using each screening method/kit both for the primary and secondary screens.

Table 3 shows the summary of screening errors by method. There were no errors or misclassifications this quarter.

In Part 2 of the report, Table 4 shows the number of laboratories using each confirmatory method/kit.

Table 5 shows the Reported Frequency of Bands by Western Blot

for each of the PT specimens that tested positive for the Anti-HIV-1 screening analysis.

The Quality Assurance Program will ship next quarter's HIV-1 DBS proficiency testing specimens October 11, 2011. ❖

CONFERENCES AND MEETINGS

United States Conference on AIDS, Chicago, IL, November 10-13, 2011.

National STD Prevention Conference, Minneapolis, Minnesota, March 12-15, 2012.

ACTHIV Conference, Denver, Colorado, May 10-13, 2012.

Congress on HIV and Emerging Infectious Diseases, Marseille, France, May 23-25, 2012.

December 1st



World AIDS Day
Public Education Program



Direct inquiries to:
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, MS/F43
Atlanta, GA 30341-3724

Quarterly publications for colleagues and participants of the Proficiency Testing Program for Anti-HIV-1 in Dried Blood Spots.

Phone: 770-488-7897
FAX: 770-488-4255
E-mail: NMeredit@cdc.gov

Editor: Nancy Meredith
Production: Connie Singleton



**Anti-HIV-1 PT Report
Quarter 3, 2011**

TABLE 1: Frequency Distribution: Outcome of Final Interpretations (#Labs)

Specimen Number	Expected Results	Non- Reactive	Reactive	Indeterminate	Not Reported
3141	Non-Reactive	25	0	0	3
3142	Non-Reactive	25	0	0	3
3143	Non-Reactive	25	0	0	3
3144	Reactive	0	25	0	3
3145	Reactive	0	25	0	3

Part 1. SCREENING

TABLE 2: Number of Screening Methods Reported; Includes Primary and Secondary Methods

Method Code	Kit Source	Participants
10	Fujirebio Serodia-HIV 1,2	2
11	In House	1
12	Other (Please specify in detail)	3
15	rLAV EIA (Bio-Rad)	1
27	Tecnosuma (Cuba) UMELISA HIV 1+2	2
34	Q-Preven HIV 1+2, DBS, Brazil	1
40	Avioq HIV-1 Microeleisa Systems	11
41	Bio-Rad HIV-1/Hiv-2 plus O EIA	2
		Total 23

Note: Two laboratories did not report EIA data and reported final interpretations based on confirmatory tests.

This **NEWBORN SCREENING QUALITY ASSURANCE PROGRAM** report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the **Centers for Disease Control and Prevention (CDC)** and the **Association of Public Health Laboratories**.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
ATLANTA, GA 30341

Director

Thomas R. Frieden, M.D., M.P.H.

Director

National Center for Environmental Health

Christopher J. Portier, Ph.D.

Director

Division of Laboratory Sciences

James L. Pirkle, M.D., Ph.D.

Chief

Newborn Screening and Molecular Biology Branch

Carla Cuthbert, Ph.D.



Contributors: Barbara W. Adam
Carol Bell
Dana Chafin
Paul Dantonio
Sharon Flores
Victor R. De Jesus, Ph.D.
Marie C. Earley, Ph.D.
Tamara Ganka
Elizabeth M. Hall
Christopher Haynes, Ph.D.
Kevin Lanza
Francis Lee, Ph.D.
Lixia Li, Ph.D.
Timothy Lim, Ph.D.
Joanne Mei, Ph.D.
Nancy Meredith
Tracey Myers
Jennifer Taylor
Robert Vogt, Ph.D.
Golriz Yazdanpanah
Hui Zhou, Ph.D.
Sherri Zobel

Production: Sarah Brown
Felicia Manning
Teresa Moore
Connie Singleton



ASSOCIATION OF PUBLIC HEALTH LABORATORIES
SILVER SPRING, MD 20910

President

Victor Waddell, Ph.D.

Chairman, Newborn Screening and Genetics in Public Health Committee

Susan M. Tanksley, Ph.D.

Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee

Gary Hoffman, B.S.

INQUIRIES TO:

Nancy Meredith, Editor • Centers for Disease Control and Prevention (CDC)
Newborn Screening Quality Assurance Program • Mailstop F-43
4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • FAX (770) 488-4255 • E-mail: NMeredith@cdc.gov